Everolimus tablets price update in 2024
Everolimus is already on the market in the country and is included in medical insurance. Patients can go to local hospitals to inquire about this drug. The latest domestic price remains between 2000-4000yuan. The relatively affordable price makes this treatment affordable for more patients.
It is worth mentioning that there are regular and legal generic versions of everolimus in India. The ingredients of these generic drugs are basically the same as the original drugs, but the latest selling prices are only between a few hundred to one thousand five hundred yuan.
Everolimus has a wide range of indications. It is suitable for postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer, especially after failure of letrozole or anastrozole treatment. It is used in combination with exemestane to provide patients with new treatment opportunities. Everolimus also shows good efficacy in the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin that are unresectable, locally advanced, or metastatic. In addition, everolimus also plays an important role in patients with advanced renal cell carcinoma who have failed treatment with sunitinib or sorafenib.
In addition to the above indications, everolimus has shown excellent results in the treatment of renal angiomyolipoma and tuberous sclerosis. Everolimus provides an effective treatment option for patients with renal angiomyolipoma and tuberous sclerosis who do not require immediate surgery.
The U.S. Food and Drug Administration approved everolimus oral suspension in 2018 for the adjunctive treatment of patients 2 years of age and older with partial-onset epilepsy associated with tuberous sclerosis complex. This approval further broadens the scope of everolimus and demonstrates its versatility in the treatment of tuberous sclerosis and its associated complications. Whether it is TSC-related subependymal giant cell astrocytoma or TSC-related renal angiomyolipoma, everolimus has demonstrated its unique therapeutic value.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)